Daiichi Sankyo gains rights to potential blockbuster cancer drug
March 2, 2011Research and Development BRAF protein, Daiichi Sankyo, PLX4032, Plexxikon, melanoma, personalised medicine
Daiichi Sankyo has purchased US-based discovery firm Plexxikon for $805 million, gaining access to its potential blockbuster melanoma drug PLX4032. …
Samsung forges biosimilar venture with Quintiles
March 2, 2011Manufacturing and Production Quintiles, Samsung, biosimilar production, biosimilars, pharma production
South Korean electronics giant Samsung has formed a joint venture with Quintiles with the objective of breaking into the market …
Fujifilm buys into bio with Merck acquisitions
March 2, 2011Manufacturing and Production Biomanufacturing, Fujifilm, Merck, Merck & Co, Merck/MSD Biomanufacturing Network, contract manufacturing
Japanese photography and imaging company Fujifilm continued its diversification into other sectors with the acquisition of the Merck/MSD Biomanufacturing Network, …
Bayer goes for pharma growth
March 1, 2011Research and Development, Sales and Marketing 2010 pharma results, Bayer, Dr Jörg Reinhardt, Marijn Dekkers, Nexavar, VEGF Trap-Eye, Xarelto
While many of its larger peers in the pharma sector are rushing to diversify into consumer health and generics, Bayer, …
Pfizer drops 15 pipeline projects
March 1, 2011Research and Development Lyrica, Pfizer, Pfizer R&D, Pfizer product pipeline, Pfizer research, inotuzumab, pregabalin
Pfizer has again slimmed down its product pipeline as the US giant looks to cut R&D spending and sharpen its …
LEO Pharma Selects Veeva CRM for Pan-European Deployments
March 1, 2011Sales and Marketing veeva
BARCELONA, SPAIN — 1 March, 2011 – LEO Pharma, a leading global pharmaceutical company specialising in dermatology and critical care, …
Dutch government sells off vaccine facility
March 1, 2011Manufacturing and Production Bilthoven, Holland, NVI, Netherlands, Netherlands Vaccine Institute, vaccine manfacturing, vaccine production, vaccines
The Dutch government has put the manufacturing activities and capacity of the Netherlands Vaccine Institute in Bilthoven up for sale, …
Catalent sells off printed components business
March 1, 2011Manufacturing and Production Catalent, Clondalkin, pharma packaging, pharmaceutical packaging
Catalent Pharma Solutions has agreed to sell its printed components business to Dutch packaging giant Clondalkin, which has been steadily …
Nampak to leave Portsmouth for new facility
March 1, 2011Manufacturing and Production Nampak Healthcare, Portsmouth, Segensworth, pharma packaging, pharmaceutical carton facility
Nampak Healthcare plans to invest in a new manufacturing facility in Segensworth, UK, to overcome the limitations of its current …
Friedhelm Felten to head procurement at Merck
March 1, 2011Manufacturing and Production, Research and Development Friedhelm Felten, Merck KGaA, appointment, manufacturing and production, research and development
Merck KGaA has appointed Friedhelm Felten as its new head of corporate procurement with responsibility for the group’s global purchasing …
Forest depression candidate struggles against placebo
March 1, 2011Research and Development Forest, Forest Laboratories, Gedeon Richter, cariprazine, depression, major depressive disorder
An investigational antipsychotic drug being developed by Forest Laboratories and Budapest-based Gedeon Richter has failed to prove itself in phase …
Pfizer in break up talks for Sandwich research site
March 1, 2011Research and Development Kent, Pfizer, Sandwich, job cuts
Pfizer is in confidential talks over the future of its Sandwich, Kent research facility that could see the site broken …
Service Insight: Discovery metrics – creating the right balance
February 28, 2011Research and Development Atkinson Cowan, Kinapse, Service Insight, metrics, research and development
SERVICE INSIGHTMetrics can be powerful tools for driving performance in organisations and have proliferated in the pharmaceutical industry over the …
David Redfern appointed ViiV chairman
February 28, 2011Research and Development, Sales and Marketing David Redfern, GSK, GlaxoSmithKline, Pfizer, ViiV, ViiV Healthcare, appointment, research and development, sales and marketing
David Redfern has been appointed as chairman of ViiV Healthcare, the joint GlaxoSmithKline-Pfizer venture focused on HIV.
Black Swan Analysis appoints Luke McDermott
February 28, 2011Sales and Marketing Black Swan Analysis, Luke McDermott, appointment, sales and marketing
Maidenhead, UK-based Black Swan Analysis has expanded its analysis and forecasting team with the appointment of Luke McDermott.He joins the …
AZ opens new global HQ in London
February 28, 2011Medical Communications, Sales and Marketing AZ, AstraZeneca, London
AstraZeneca has moved its London global headquarters from Mayfair to new, larger premises in Paddington. The new offices are located …
Healthcare IT and patients: lessons from the NHS experience
February 28, 2011Medical Communications, Sales and Marketing Healthcare IT, NHS, NHS IT, electronic patient records, online health information
Many countries are investing heavily in electronic health records and health information exchange to drive improvements in the quality of …
Vertex’s cystic fibrosis drug shows huge promise
February 28, 2011Research and Development, Sales and Marketing VX-770, Vertex, cystic fibrosis
US pharma company Vertex has announced extremely promising results for a drug that could be a major advance in treating …
New agreement seeks to speed up UK research
February 25, 2011Research and Development BIA, Industry Collaborative Research Agreement, MRC, Medical Research Council, National Institute for Health Research, Office for Clinical Research Infrastructure, UK research, clinical research, mICRA
The government has revised the research contracting process in a bid to streamline research between pharma and biotech companies, universities …
MPs to question Pfizer management over R&D closure
February 25, 2011Research and Development Kent, Pfizer, Sandwich, Science and Technology Select Committee, research and development
Senior Pfizer executives will appear before MPs next week to answer questions on the closure of the company’s Kent research …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
